Shanghai Medicilon Inc. (SHA:688202)
74.22
-5.88 (-7.34%)
Nov 16, 2026, 4:00 PM EST
Shanghai Medicilon Revenue
Shanghai Medicilon had revenue of 453.50M CNY in the quarter ending September 30, 2026, with 49.89% growth. This brings the company's total for the last twelve months to 1.54B, up 42.27% year-over-year. In the year 2025, Shanghai Medicilon had annual revenue of 1.16B with 12.08% growth. That makes Shanghai Medicilon the 16,493rd largest company in the world by revenue and 2,989th in China.
Revenue (ttm)
1.54B
Revenue Growth
+42.27%
P/S Ratio
6.36
Revenue / Employee
613.05K
Employees
2,780
Market Cap
9.76B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Shanghai Medicilon breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.16B | 125.32M | 12.08% |
| Dec 31, 2024 | 1.04B | -327.89M | -24.01% |
| Dec 31, 2023 | 1.37B | -293.30M | -17.68% |
| Dec 31, 2022 | 1.66B | 491.67M | 42.12% |
| Dec 31, 2021 | 1.17B | 501.31M | 75.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tibet Cheezheng Tibetan Medicine | 2.23B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.16B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Nanjing Vazyme Biotech | 1.56B |
| Shanghai OPM Biosciences | 822.13M |
| Chongqing Genrix Biopharmaceutical | 800.98M |
| Chengdu Olymvax Biopharmaceuticals | 796.18M |
| Mabwell (Shanghai) Bioscience | 717.80M |